Stress Cardiomyopathy Complicated by Left Ventricular Thrombi and Cerebral Infarctions in a Patient with Essential Thrombocythemia by Hwang, Seung Hwan et al.
87
Introduction
Stress induced cardiomyopathy (SCMP) is characterized by 
a transient left ventricular (LV) dysfunction with akinesis and 
systolic expansion of apical segments and hyperkinesis or nor-
mokinesis of the basal segments. Various emotional or physi-
cal stressors have been described as triggering factors of this 
syndrome. Although the prognosis of SCMP is generally 
known to be excellent, several fatal complications have been 
described. Here, we report a rare case of SCMP complicated 
by LV thrombosis and multiple cerebral infarctions in a pa-
tient with essential thrombocythemia (ET).
Case
A 75-year-old female presented with sudden onset of men-
tal deepening, hemiparesis, and dysarthria which developed 1 
hour ago. She had a history of dural sinus thrombosis and 
deep vein thrombosis 2 years ago, and the cause of venous 
thrombosis was ET. She had been treated with 0.5 mg of 
anagrelide and 500 mg of hydroxyurea daily for ET at hema-
tologic department for last 2 years. Before 1 day of admission, 
she had experienced severe emotional stress due to arguments 
with her husband for economic problems, and thereafter chest 
tightness developed and persisted. Brain magnetic resonance 
imaging revealed acute infarctions of left middle cerebral and 
right posterior inferior cerebellar arterial territories (Fig. 1). 
Electrocardiogram (ECG) at admission showed convex ST 
segment elevation and T-wave inversions in precordial leads 
with QT prolongation. Laboratory studies showed thrombo-
cytosis with platelet count of 665 × 103/mm3 and mildly ele-
vated cardiac troponin I with the level of 0.65 ng/mL. Other 
laboratory findings were unremarkable. Transthoracic echocar-
diography (TTE) was performed to evaluate cardiac abnormal-
ities relevant to the abnormalities of ECG and cardiac en-
zymes, and cardiac source of cerebral embolism. TTE revealed 
akinesia and systolic bulging of the apical segments with hy-
perkinetic basal wall motions, and the estimated ejection frac-
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tion was 51.8%. About 3.3 × 2.4 cm sized mural thrombus 
was observed within the dyskinetic apical segments of the LV 
(Fig. 2A and B). Coronary angiography was performed to ex-
clude acute myocardial infarction (AMI) and revealed no sig-
nificant stenotic lesions in both coronary arteries. The most 
probable diagnosis in the present case was SCMP with apical 
mural thrombi complicated by multiple cerebral infarctions 
in the setting of ET. Anticoagulation with intravenous hepa-
rin and general managements for heart failure and cerebral in-
farctions were done without discontinuation of anagrelide and 
hydroxyurea. The symptoms and signs of cerebral infarctions 
including motor and speech disturbances were improved 
gradually. The wall motion abnormalities of the LV apex were 
improved, and the thrombus was disappeared on follow-up 
TTE (Fig. 2C and D). The patients was discharged with med-
ications including anagrelide and hydroxyurea and managed 
at out-patient clinic without any clinical events.
Discussion
SCMP, also known as apical ballooning or Takotsubo car-
diomyopathy, is a syndrome of transient cardiac dysfunction 
associated with acute emotional or physical stress, but the 
pathogenesis of SCMP is not well established. Catecholamine-
mediated multivessel epicardial or microvascular coronary va-
sospasm or direct catecholamine-mediated myocyte injury has 
been proposed as possible pathophysiological mechanisms.1) 
Fig. 1. Diffusion weighted (A and C) and apparent diffusion coefficient (B and D) brain magnetic resonance imaging show acute cerebral infarction in 
the left middle cerebral artery territory (A and B, arrow) and right posterior inferior cerebellar artery territory (C and D, arrow).
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Because clinical characteristics of SCMP are quite similar to 
those of AMI, the differential diagnosis between SCMP and 
AMI is very difficult and usually requires coronary angiogra-
phy.2) Coronary angiography was also performed in the present 
case to rule out AMI as a cause of LV dysfunction and revealed 
normal coronary circulation. Provocation test for vasospasm 
was not performed, because vasoactive drugs including intra-
venous nitrates were prescribed already. Therefore, the possi-
bility of vasospasm as a cause of wall motion abnormality 
could not completely rule out in the present case.
Emotional stress, as in most of the previously reported cases, 
was the most probable predisposing cause of SCMP in the 
present case, but the role of anagrelide should also be consid-
ered. Anagrelide inhibits platelet aggregation through the se-
lective inhibition of type III cyclic adenosine monophosphate 
phosphodiesterase on the megakaryocyte cell lineage, and thus 
anagrelide used in the treatment of ET to prevent the inci-
dence of thromboembolic events. Because it may have positive 
inotropic and chronotropic activity, and directly induce vaso-
spasm of the coronary arteries, several serious cardiovascular 
side effects including congestive heart failure, arrhythmia, 
acute coronary syndrome, and SCMP has been described.3) 
These side effects of anagrelide developed usually within 1 
month of medication and decreased with improved tolerance 
to treatment over time in the previous report.3)4) Because 
anagrelide had been prescribed for last two years without any 
side effects in the present case, it is assumed that the role of 
anagrelide in the development of SCMP might be negligible 
in the present case. Therefore, anagrelide and hydroxyurea were 
prescribed continuously in the present case during admission 
and after discharge. Because the platelet count of the patient 
was maintained in acceptable range with the combination 
therapy of relatively low dose of anagrelide (0.5 mg) and hy-
droxyurea, we did not change the dosage of anegrelide. If the 
platelet count is not controlled within acceptable range, it 
would be reasonable to adjust the dosage of anegrelide. In case 
of confirmed acute coronary syndrome, the discontinuation of 
anagrelide has been recommended.5)
Although the prognosis of SCMP is known to be excellent, 
various complications, including severe heart failure with pul-
monary edema, shock and inhospital death have been report-
ed. The present case presented with multiple cerebral infarc-
tion presumably caused by the embolization of the LV thrombi, 
and cerebral infarction associated with LV thrombosis is a rare 
Fig. 2. Transthoracic echocardiography at admission reveals akinesia and systolic bulging of apical segments with thrombi formation (A and B, 
arrow). The wall motion abnormalities of the left ventricular are normalized and the apical thrombi are resolved completely on follow-up 
echocardiographic examination (C and D).
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complication of SCMP. In a recent systematic review of de 
Gregorio,6) LV thrombosis occurred approximately 5% of the 
patients with SCMP, and one third of them experienced 
thromboembolic events. The study of Haghi et al.7) and Mit-
suma et al.8) also demonstrated that LV thrombosis and subse-
quent embolism was a possible complication of SCMP. Recent 
meta-analysis showed that LV thrombus is a significant com-
plication and systemic embolism is 2nd common causes of 
mortality in SCMP.9) Therefore, it is suggested that the early 
initiation of anti-coagulation therapy to prevent LV thrombo-
sis and subsequent embolic complications would be a reason-
able approach in patients with SCMP.
The LV thrombosis in patients with SCMP is probably 
caused by low blood flow in the left ventricle as well as LV sys-
tolic dysfunction. ET is known to be associated with bleeding 
or thromboembolic complications. Arterial thromboses occur-
ring in coronary, cerebral or peripheral arteries are regarded as 
more typical than venous thromboembolic events in patients 
with ET. The present case had a tendency of thrombosis evi-
denced by the previous history of dural sinus and deep vein 
thrombosis associated with ET, and thus ET might play an im-
portant additional role in the thrombus formation within the 
LV in the present case, besides SCMP itself. Baker et al.10) also 
reported a similar case of LV mural thrombus in a patient with 
thrombocytosis and agnogenic myeloid metaplasia.
In conclusion, we report a rare case of SCMP complicated 
by LV thrombosis and multiple cerebral infarctions in a pa-
tient with ET. Early initiation of anti-coagulation therapy 
should be considered in patients with SCMP, especially who 
had combined coagulation disorders such as ET.
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